Last reviewed 2026-04-23 · How we verify

Docetaxel and Reolysin

Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells.

Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells. Used for Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.

At a glance

Mechanism of action

Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Reolysin, on the other hand, is a recombinant reovirus that selectively infects and kills cancer cells by inducing apoptosis and inhibiting angiogenesis.

Approved indications

• Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer

Common side effects

• Neutropenia
• Fatigue
• Nausea
• Diarrhea
• Anemia

Key clinical trials

• Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer (PHASE2)
• Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Docetaxel and Reolysin CI brief — competitive landscape report
• Docetaxel and Reolysin updates RSS · CI watch RSS
• Canadian Cancer Trials Group portfolio CI